-
Oct 3, 2024 | 
rxlist.com | Merck Sharp
What Is Prevymis?
Prevymis (letermovir) is a CMV DNA terminase complex inhibitor indicated for prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT).
What Are Side Effects of Prevymis?
-
Aug 19, 2024 | 
rxlist.com | John P. Cunha |Merck Sharp
What Is Keytruda?
-
Jul 3, 2024 | 
rxlist.com | Merck Sharp
What Is Capvaxive?
Capvaxive (pneumococcal 21-valent conjugate vaccine) is a vaccine indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in individuals 18 years of age and older; and active immunization for the prevention of pneumonia caused by S.
-
Jun 18, 2024 | 
trialbulletin.com | Merck Sharp
OverviewResearchers are looking for ways to treat a type of liver disease caused by elevated liver
fat, called metabolic dysfunction-associated steatohepatitis (MASH). MASH was formerly called
non-alcoholic steatohepatitis (NASH).
-
Jun 14, 2024 | 
trialbulletin.com | Merck Sharp
OverviewThe purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and
preliminary efficacy of MK-6837, administered as a monotherapy and in combination with
pembrolizumab (MK-3475), in participants with histologically or cytologically confirmed
advanced/metastatic solid tumors that have not responded to conventional therapy. There will
not be any hypothesis testing in the study.
-
Jun 4, 2024 | 
trialbulletin.com | Merck Sharp
OverviewThe purpose of this study is to compare the plasma pharmacokinetics (PK) of nemabrutinib
(MK-1026) following a single oral dose of nemtabrutinib in participants with moderate hepatic
impairment to that of healthy matched control participants and to evaluate the safety and
tolerability of nemtabrutinib.
-
May 20, 2024 | 
trialbulletin.com | Merck Sharp
OverviewThis is a phase 3 study of pembrolizumab in combination with carboplatin/taxane (paclitaxel
or nab-paclitaxel) followed by pembrolizumab with or without maintenance sacituzumab
tirumotecan (sac-TMT; MK-2870) in first-line treatment of metastatic squamous non-small cell
lung cancer. It is hypothesized that pembrolizumab with maintenance sacituzumab tirumotecan
is superior to pembrolizumab without sacituzumab tirumotecan maintenance with respect to
overall survival (OS).
-
May 1, 2024 | 
trialbulletin.com | Merck Sharp
OverviewSubstudy 01A is part of a platform study. The purpose of this study is to assess the efficacy
and safety of zilovertamab vedotin in pediatric participants with elapsed or refractory
B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt
lymphoma, or neuroblastoma and in pediatric and young adult participants with Ewing sarcoma.
-
May 1, 2024 | 
trialbulletin.com | Merck Sharp
OverviewThis study is a rolling arm study of pembrolizumab in combination with investigational agents
in pediatric participants with relapsed or refractory classical Hodgkin lymphoma (cHL), solid
tumors with microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) or tumor
mutational burden-high (TMB-H), or advanced melanoma.
-
Apr 29, 2024 | 
rxlist.com | Merck Sharp
Description for Winrevair
Sotatercept-csrk is a homodimeric recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA (ActRIIA) linked to the human IgG1 Fc domain. The molecular weight based on the amino acid sequence of sotatercept-csrk is approximately 78 kDa as a homodimer.
